Core Insights - Capricor Therapeutics announced positive four-year safety and efficacy results for Deramiocel, its lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD) [1][3] - The findings will be presented at the PPMD 2025 Annual Conference, highlighting the importance of addressing both cardiac and skeletal muscle functions in DMD treatment [1][4] Efficacy Results - After four years of treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline, indicating clinical benefit, especially in patients with baseline LVEF >45% [2] - The treatment also slowed skeletal muscle disease progression, with a smaller average decline in Performance of the Upper Limb (PUL v2.0) in the fourth year (0.6 points) compared to the first year (1.8 points) [3][7] Safety Profile - Deramiocel maintained a favorable safety profile throughout the study, reinforcing its potential as a therapeutic option for DMD [3][7] Regulatory Progress - Capricor is in the process of obtaining regulatory approval for Deramiocel, with its Biologics License Application (BLA) under priority review and no evidence of delays in discussions with the FDA [4][10] Study Background - The HOPE-2 study was a randomized, double-blind, placebo-controlled Phase 2 trial, with patients receiving intravenous infusions of Deramiocel (150 million cells) every three months [5] - Following the study, all patients entered a treatment gap phase before enrolling in the HOPE-2 Open-Label Extension (OLE) study, which continues to monitor safety and efficacy [5] About Duchenne Muscular Dystrophy - DMD is a severe genetic disorder affecting approximately 15,000 individuals in the U.S., characterized by progressive muscle degeneration and leading to cardiomyopathy, which is a major cause of mortality [6][9] About Deramiocel - Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs) known for their immunomodulatory and anti-fibrotic properties, which may help preserve cardiac and skeletal muscle function in DMD [8][10] - The therapy has received multiple designations from regulatory agencies, including Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation [9]

Hello, and welcome to the presentation on Independent Control of AI Engine Partitions. In this Tech module, we’ll start with an introduction to AI Engine independent partitioning. Next, we’ll cover the AI Engine kernel workflow, detailing the process of compilation, linking, and packaging.We’ll then dive into modular control over partition management and reloading, discussing the flexibility it offers for efficient development. After that, we’ll go through key system considerations, highlighting what’s avai ...

Investor Day & Longevity Summit June 12, 2025 abacusgm.com Disclaimer General. This presentation (this "Presentation") is provided solely for informational purposes. This Presentation is subject to update, completion, revision, verification and further amendment without notice. None of Abacus Global Management, Inc. (the "Company", "Abacus", Abacus Global Management", "we", "our", or "us") or its affiliates has authorized anyone to provide interested parties with additional or different information. The inf ...

Lavoro Limited (LVRO) Q2 2025 Earnings Call June 18, 2025 05:00 PM ET Speaker0 Welcome to Lovallo's Business Update Conference Call. Please note that this conference call is being recorded and a replay will be made available on the company's Investor Relations website at ir.lavoroagro.com. I will now turn the conference over to Tigran Karpishin, Head of Investor Relations. Thank you. You may begin. Speaker1 Thank you for joining us today to discuss our business update. We will be covering the out of court r ...

SAXONBURG, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in photonics, today announced the launch of its new line of disposable surgical fiber assemblies designed specifically for a wide range of precision medical applications. The new product line is suitable for both OEM integration and for direct clinical use. Engineered to meet the rigorous demands of modern surgical environments, the new fiber assemblies deliver exceptional optical performance, robust durability, a ...

[Music] On June 13th, the Environmental Protection Agency released its long-awaited renewable volume obligation proposal for 2026 and 2027 under the renewable fuel standard. The proposal will greatly increase the required volume of biomassbased diesel blended by refiners from 3.35% billion gallons in 2025 to 5.61% 61 billion gallons in 2026 and 2027. The proposal also prioritizes using soybean oil and ethanol produced in the United States and discourages the use of biomass and feed stocks produced outside o ...

When my grandmother passed away last year at 100 years old, I sat with the truth of her life and her legacy. Aside from being a wife, a passionate teacher, a mother of five, a grandmother of 22, and a great grandmother of 17. What really struck me was how she thrived.No chronic illnesses, no prescription pills, no confusion about what to eat. She ate from the land. She cooked from home.She trusted what she knew. Wisdom passed on from generations before her. Her quality of life got me thinking, when did some ...

गुड इवनिंग एवरीवन। अ फ्यू मंथ्स बैक इन अ स्टूडेंट लेड कॉन्फ्रेंस इन यंग गर्लफ ऑफ ग्रेट सेन पुट अप एंड शेयरर्ड अबाउट क्रिएटिंग अ पीस गार्डन ऑन कैंपस। अ स्पेस फॉर रिफ्लेक्शन क्वाइट एंड कनेक्शन विद नेचर आल्सो शेयरर्ड दैट वी डोंट नीड मोर क्लासरूम्स रादर वी नीड मोर स्पेसेस टू थिंक एंड दैट अकॉर्डिंग टू मी इज विज़डम व्हिच कैन नॉट बी टॉट थ्रू टेक्स्ट बुक बट नर्चर इन द राइट एनवायरमेंट टुडे वी लिव इन द टाइम्स दैट आर ट्रांसफॉर्मिंग एव्री मिनट बीट आर्टिफिशियल इंटेलिजेंस बीट ग्लोबल कॉन्फ्लिक्ट्स एंड बी इट रिवोल्यूशन ऑफ ड ...

Core Insights - RIBER reaffirms its strategic roadmap during the Annual General Meeting, emphasizing a culture of excellence, continuous innovation, and strong customer focus to position itself at the forefront of the semiconductor industry's transformations, particularly in silicon-based integrated photonics [1][4]. Group 1: Strategic Developments - RIBER introduced ROSIE (Riber Oxide Silicon Epitaxy), an advanced platform for oxide growth on 300 mm wafers, which is fully compatible with SEMI standards, marking a significant technological breakthrough [2]. - The industrialization phase of ROSIE has commenced following a strategic partnership with the Novo Nordisk Foundation Quantum Computing Programme, which includes the qualification of the ROSIE process and the sale of the first unit scheduled for the second half of 2025 [2][3]. Group 2: Financial and Operational Highlights - The Annual General Meeting approved the statutory and consolidated financial statements for the 2024 financial year, along with a cash payout of €0.08 per share, with the ex-dividend date set for June 23, 2025 [6]. - RIBER's strategic positioning is strengthened by solid commercial momentum for its MBE equipment and the industrial rollout of ROSIE, enhancing growth and diversification potential in the semiconductor sector [4]. Group 3: Market Focus - RIBER targets several fast-growing markets, including ultra-fast optical communications, optical computing, and photonic quantum technologies, reflecting its commitment to innovation in the semiconductor industry [7]. - The company plays a crucial role in the development of advanced semiconductors used in various applications, from information technologies to 5G telecommunications networks and quantum computing [8].

Core Insights - VEON Ltd. announces that Kyivstar has received regulatory approval for testing Starlink Direct-to-Cell (D2C) services in Ukraine, marking a significant step towards enhancing connectivity in the region [1][4] - Successful integration of Kyivstar's SIM cards with Starlink's satellite network has been confirmed, indicating compatibility and paving the way for the launch of D2C services [2] - The planned launch of D2C services, which will support SMS and over-the-top (OTT) messaging, is set for Q4 2025, aimed at improving connectivity in areas affected by infrastructure damage and during emergencies [3] Company Overview - VEON is a digital operator serving nearly 160 million customers across six countries, focusing on technology-driven services that promote economic growth [5] - Kyivstar, as Ukraine's largest digital operator, serves over 23 million mobile subscribers and has committed to investing USD 1 billion in telecom technologies from 2023 to 2027 [6] - Kyivstar has allocated over UAH 2 billion in the past two years to support wartime challenges, including assistance to the Armed Forces and social projects [6]